Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MAT2A | P31153 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862937 | 0.85 | PDE4A (0.59) | PDE5A | |
| SCHEMBL715585 | 0.79 | PDE5A (1.00) | PDE5AHTR3AHRH4TBXAS1PDE3B | |
| Hydrochloric Acid SCHEMBL7280241 | 0.78 | PDE5A (1.00) | PDE5AHTR3AHRH4TBXAS1PDE3B | |
| SCHEMBL5595125 | 0.76 | PDE5A (0.69) | PDE5AHTR3AHRH4TBXAS1PDE3B | |
| Hydrochloric Acid SCHEMBL7278512 | 0.76 | PDE5A (0.69) | PDE5AHTR3AHRH4TBXAS1PDE3B | |
| SCHEMBL3638867 | 0.75 | PDE5A (0.73) | PDE5AHTR3AHRH4MAT2A | |
| SCHEMBL5598640 | 0.75 | CSF1R (0.48) | PDE5A | |
| SCHEMBL4652135 | 0.74 | PDE5A (0.49) | PDE5AHTR3AHRH4MAT2A | |
| SCHEMBL2590769 | 0.73 | RAD52 (0.68) | PDE5AHTR3AHRH4 | |
| SCHEMBL7287234 | 0.72 | PDE5A (0.85) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-8263555-B2 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| US-6294550-B1 | ADMINISTERING A VASOACTIVE AGENT FROM ERGOTAMINE DRUG | ASIVI, LLC | 2001-09-25 | — | — | US | disclosed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE5A 302/4885HTR3A 491/4885HRH4 36/4885 |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | PDE5A 2/4885HTR3A 465/4885HRH4 3599/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE5A 3481/4885HTR3A 4130/4885HRH4 3447/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | PDE5A 4/4885HTR3A 245/4885HRH4 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.